7
IRUS Total
Downloads

Lentiviral gene therapy rescues p47phox chronic granulomatous disease and the ability to fight Salmonella infection in mice

File Description SizeFormat 
Lentiviral gene therpay rescues p47phox chronic granulomatous disease.pdfPublished version1.53 MBAdobe PDFView/Open
Title: Lentiviral gene therapy rescues p47phox chronic granulomatous disease and the ability to fight Salmonella infection in mice
Authors: Schejtman, A
Aragão-Filho, WC
Clare, S
Zinicola, M
Weisser, M
Burns, SO
Booth, C
Gaspar, HB
Thomas, DC
Condino-Neto, A
Thrasher, AJ
Santilli, G
Item Type: Journal Article
Abstract: Chronic granulomatous disease (CGD) is an inherited primary immunodeficiency disorder characterised by recurrent and often life-threatening infections and hyperinflammation. It is caused by defects of the phagocytic NADPH oxidase, a multicomponent enzyme system responsible for effective pathogen killing. A phase I/II clinical trial of lentiviral gene therapy is underway for the most common form of CGD, X-linked, caused by mutations in the gp91phox subunit of the NADPH oxidase. We propose to use a similar strategy to tackle p47phox-deficient CGD, caused by mutations in NCF1, which encodes the p47phox cytosolic component of the enzymatic complex. We generated a pCCLCHIM-p47phox lentiviral vector, containing the chimeric Cathepsin G/FES myeloid promoter and a codon-optimised version of the human NCF1 cDNA. Here we show that transduction with the pCCLCHIM-p47phox vector efficiently restores p47phox expression and biochemical NADPH oxidase function in p47phox-deficient human and murine cells. We also tested the ability of our gene therapy approach to control infection by challenging p47phox-null mice with Salmonella Typhimurium, a leading cause of sepsis in CGD patients, and found that mice reconstituted with lentivirus-transduced hematopoietic stem cells had a reduced bacterial load compared with untreated mice. Overall, our results potentially support the clinical development of a gene therapy approach using the pCCLCHIM-p47phox vector.
Issue Date: 1-Sep-2020
Date of Acceptance: 2-Jun-2020
URI: http://hdl.handle.net/10044/1/80829
DOI: 10.1038/s41434-020-0164-6
ISSN: 0969-7128
Publisher: Springer Nature [academic journals on nature.com]
Start Page: 459
End Page: 469
Journal / Book Title: Gene Therapy (Basingstoke)
Volume: 27
Copyright Statement: © The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Sponsor/Funder: Wellcome Trust
Funder's Grant Number: 206617/A/17/Z
Keywords: Science & Technology
Life Sciences & Biomedicine
Biochemistry & Molecular Biology
Biotechnology & Applied Microbiology
Genetics & Heredity
Medicine, Research & Experimental
Research & Experimental Medicine
ACTIVATION
PROMOTER
VECTOR
LEADS
Biotechnology
06 Biological Sciences
11 Medical and Health Sciences
Publication Status: Published
Conference Place: England
Online Publication Date: 2020-06-12
Appears in Collections:Department of Immunology and Inflammation
Faculty of Medicine